BioMarin Pharmaceutical Inc.

Valuation Analysis

About the Company

BioMarin Pharmaceutical Inc. en bref

BioMarin Pharmaceutical Inc. (BMRN) is currently trading at 47,68 € with a market capitalization of 9,2 Md €. The trailing P/E ratio stands at 39.35x, with a forward P/E of 8.46x. The 52-week range spans from 42,94 € to 57,78 €; the current price is 17.5% below the yearly high. Year-over-year revenue growth stands at +2.8%. The net profit margin stands at 8.29%.

💰 Dividende

BioMarin Pharmaceutical Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

26 analystes évaluent BioMarin Pharmaceutical Inc. (BMRN) au consensus : Acheter. L'objectif de cours moyen est de 76,58 €, soit un potentiel de +60.63% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 43,59 € à 104,61 €.

BioMarin Pharmaceutical Inc. : la thèse d'investissement en détail

BioMarin Pharmaceutical Inc. (BMRN) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

The combination of a 51.16% gross margin and 18% operating margin shows the business converts revenue into profit efficiently — a hallmark of competitive moat. Wall Street consensus sits at Buy with an average price target implying roughly 60.63% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Revenue growth has slowed to just 2.8%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valorisation en contexte

With a PEG ratio of 0.68, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

À surveiller

• The forward P/E of 8.46x is meaningfully below the trailing 39.35x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 60.63% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (6.02%).

Trading Data

Related Stocks in the Same Sector

Where can I buy BioMarin Pharmaceutical Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.